Pemafibrate vs fenofibrate vs placebo in dyslipidemia (high TG, low HDL-C)

Phase 3, randomised, double-blind trial of pemafibrate in hypertriglyceridemia, dyslipidemia and familial hypercholesterolemia (FH) (3 arms), sponsored by Xinghe Corporation. Primary endpoints: Percent change in fasting triglycerides from baseline to Week 8 and Percent change in fasting triglycerides from baseline to Week 12. Started Aug 2021; status: completed.